Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Fötale Reparatur komplexer Gastroschisis: Eine Sicherheits- und Durchführbarkeitsstudie

4. November 2026 aktualisiert von: Sundeep Keswani, Baylor College of Medicine

The goal of this clinical trial is to evaluate the safety and feasibility of fetal repair of complex gastroschisis (GS) via a fetoscopic surgical approach by assessing maternal, fetal, neonatal, and infant outcomes in a cohort of 10 patients. The hypothesis is that in utero repair of GS will reduce postnatal mortality and morbidity in complex GS infants with minimal maternal and fetal risk.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Gastroschisis is a congenital abdominal wall defect by which the intestinal structures eviscerate from the abdomen, with a current prevalence of 4.9 per 10,000 pregnancies in the United States. Not only is it the most common abdominal wall defect, but the incidence of GS has increased by nearly 30% in the US (Jones et al., 2016) and 25 % in Europe (EUROCAT, 2021) between 2006 and 2012 for reasons that are still unknown. Two subtypes of the disease have been identified - simple and complex GS. Simple GS presents as an otherwise healthy bowel that may have an inflammatory peel over the bowel surface. By contrast, complex GS is characterized by serious bowel complications, such as bowel volvulus, atresia, stenosis, necrosis, and perforation.

Participants will be offered the minimally invasive in-utero repair technique as an alternative to the traditional standard postnatal GS surgical repair. To try to help relax the abdominal wall muscles, fetuses enrolled in the trial will receive botulinum toxin type A (Botox) injections one to two weeks before the fetoscopic surgery to repair the defect. During surgery, the mother's uterus is opened using the standard laparotomy approach that we currently use in our open fetal surgeries and fetoscopic spina bifida repair through an exteriorized uterus, and then fetal surgeons repair the fetus' defect. The uterus is closed, and the pregnancy continues. When babies are treated in this way, they may be less likely to be born with their intestines coming out of their belly and if this is the case, they may be less likely to have other problems that occur with gastroschisis because the intestines are not covered.

All participants will be closely followed with ultrasound and consultation after the surgery. Delivery will be scheduled at Texas Children's Hospital, and the infants will be followed for 12 months by our research team.

Studientyp

Interventionell

Einschreibung (Geschätzt)

10

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Becky Johnson
  • Telefonnummer: 832-826-7451
  • E-Mail: rj2@bcm.edu

Studieren Sie die Kontaktsicherung

Studienorte

  • Vereinigte Staaten
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • Rekrutierung
        • Texas Children's Hospital
        • Unterermittler:
          • Roopali Donepudi, MD
        • Kontakt:
          • Becky Johnson
          • Telefonnummer: 832-826-7451
          • E-Mail: rj2@bcm.edu
        • Unterermittler:
          • Luc Joyeux, MD, PhD
        • Kontakt:
        • Unterermittler:
          • Michael A Belfort, MD, PhD
        • Unterermittler:
          • Larry Hollier Jr., MD
        • Unterermittler:
          • Timothy Lee, MD
        • Unterermittler:
          • Alice King, MD
        • Unterermittler:
          • Magdalena Sanz Cortes, MD, PhD
        • Unterermittler:
          • Ahmed Nassr, MD, PhD
        • Unterermittler:
          • Jonathan Castillo Porter, MD, MPH
        • Unterermittler:
          • Caitlin Sutton, MD
        • Hauptermittler:
          • Sundeep Keswani, MD
        • Unterermittler:
          • Becky Johnson, MS, CCRP

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  1. Pregnant women - maternal age 18 years or older and capable of consenting for her own participation in this study

  2. Singleton pregnancy

  3. Sonographic evidence of gastroschisis (exteriorization of bowel content outside the fetal abdominal cavity into the amniotic cavity)

  4. Intraabdominal bowel dilation ≥ 8 mm at 20-24 weeks GA reviewed by prenatal ultrasound

  5. Absence of significant associated anomalies* diagnosed on prenatal ultrasound or MRI

  6. Gestational age at the time of the procedure will be between 20 0/7 weeks and 27 6/7 weeks

  7. Absence of chromosomal and clinically significant abnormalities, i.e., normal karyotype and/or normal chromosomal microarray (CMA) by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). If there is a balanced translocation with normal CMA with no other anomalies the candidate can be included. Results by fluorescence in situ hybridization (FISH) will be accepted, if the candidate's gestation age is ≥ 22 0/7 weeks. Patients declining invasive testing will be excluded

  8. The family has considered and declined the option of termination of the pregnancy at less than 24 weeks and of standard postnatal treatment

  9. The family meets psychosocial criteria (sufficient social support, ability to understand the requirements of the study)

  10. Parental/guardian permission (informed consent) for follow up of the child after birth

    • Significant associated anomalies are defined as such anomalies that would, in and of themselves, be life limiting or life threatening. A minor anomaly, such as a small VSD or ASD not deemed to be life limiting or threatening, or a cleft lip or other such anomaly, unless part of a genetic syndrome, will not disqualify the patient.

Exclusion Criteria:

  1. Significant fetal anomaly unrelated to gastroschisis
  2. Evidence of bowel perforation (presence of intraabdominal bowel calcification on ultrasonography)
  3. Increased risk for preterm labor including short cervical length (≤ 2.0 cm), history of incompetent cervix with or without cerclage, and previous preterm birth in a singleton pregnancy (other than a patient delivered for a non-repeating medical or surgical indication)
  4. Placental abnormalities (previa, abruption, accreta) known at time of enrollment
  5. Pre-pregnancy body-mass index (BMI) ≥40
  6. Contraindications to surgery including previous hysterotomy (whether from a previous classical cesarean, uterine anomaly such as an arcuate or bicornuate uterus, major myomectomy resection, or previous fetal surgery) in active uterine segment
  7. Technical limitations precluding fetoscopic surgery, such as extensive uterine fibroids, fetal membrane separation, or uterine anomalies
  8. Maternal-fetal Rh alloimmunization, Kell sensitization, or neonatal alloimmune thrombocytopenia affecting the current pregnancy.
  9. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment
  10. Maternal medical condition that is a contraindication to surgery or general anesthesia
  11. Low amniotic fluid volume (Amniotic Fluid Index less than 6 cm) if deemed to be due to fetal anomaly, poor placental perfusion or function, or membrane rupture. Low amniotic fluid volume that responds to maternal hydration is not an exclusion criterion
  12. Patient does not have a support person (i.e., spouse, partner, or mother) available to support her for the duration of the pregnancy
  13. Inability to comply with the travel and follow-up requirements of the trial
  14. Patient scores as severely depressed on the Edinburgh Postnatal Depression Scale (EPDS)
  15. Patients that are enrolled or have been enrolled in any another intervention study that affects the mother or fetus
  16. Maternal hypersensitivity to any of the entities associated w/ AlloDerm™. The use of AlloDerm™ Regenerative Tissue Matrix distributed by Allergan Aesthetics is contraindicated for patients sensitive to any of the antibiotics listed on the AlloDerm package, i.e., Gentamycin, Cefoxitin, Lincomycin, Polymyxin B and Vancomycin or Polysorbate 20

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Machbarkeit des Geräts
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: fetoscopic surgical repair

Single arm study. All patients will receive the fetoscopic repair.
Gerät: fetoscopy

The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Successful Repair of Complex Gastroschisis
Zeitfenster: At end of surgical repair

Success of primary skin closure after complete bowel reduction.
At end of surgical repair

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Intrauterine Fetal Death (IUFD)
Zeitfenster: At delivery

Demise of fetus while still in the womb
At delivery
Preterm Birth
Zeitfenster: At delivery

Number of patients that deliver at < 37 weeks gestation
At delivery
Time to initiation of enteral feeds (days)
Zeitfenster: At hospital discharge, an average of 1.5 months

The number of days until initiation of enteral feeding
At hospital discharge, an average of 1.5 months
Time on total parenteral nutrition (TPN) (days)
Zeitfenster: At hospital discharge, an average of 1.5 months

The number of days on total parenteral nutrition (TPN)
At hospital discharge, an average of 1.5 months
Necrotizing Enterocolitis
Zeitfenster: At hospital discharge, an average of 1.5 months

As measured by presence in medical record
At hospital discharge, an average of 1.5 months
Short Bowel Syndrome
Zeitfenster: At hospital discharge, an average of 1.5 months

As measured by presence in medical record
At hospital discharge, an average of 1.5 months
Length of Hospital Stay
Zeitfenster: At the time of discharge from the NICU, an average of 1.5 months

Length of stay in the hospital measured in days
At the time of discharge from the NICU, an average of 1.5 months
Intracranial hemorrhage
Zeitfenster: During first month of life

Measured as presence in neonate during first month by MRI and/or ultrasound.
During first month of life
Retinopathy of Prematurity
Zeitfenster: At the time of discharge from the NICU, an average of 1.5 months

Postnatal grade classification presence of grade III or higher using standardized system (yes/no)
At the time of discharge from the NICU, an average of 1.5 months
Respiratory Distress Syndrome
Zeitfenster: At the time of discharge from the NICU, an average of 1.5 months

As measured by presence in medical record
At the time of discharge from the NICU, an average of 1.5 months
Bronchopulmonary Dysplasia
Zeitfenster: At the time of discharge from the NICU, an average of 1.5 months

As measured by presence in medical record
At the time of discharge from the NICU, an average of 1.5 months
Need for Gastroschisis related surgery
Zeitfenster: 12 months of age

As measured by presence in medical record ≤12 months
12 months of age
Small Bowel Obstruction
Zeitfenster: 12 months of age

As measured by presence in medical record ≤12 months
12 months of age
Central Line Associated Bloodstream Infection (CLABSI)
Zeitfenster: 12 months of age

As measured by presence in medical record ≤12 months
12 months of age
Neuro-developmental Outcome at 12 months
Zeitfenster: 12 months of age

As measured by the Capute Scales at 12 months
12 months of age
Survival at 12 months
Zeitfenster: 12 months of age

Number of patients alive at 12 months of age
12 months of age

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Baylor College of Medicine

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. Oktober 2023

Primärer Abschluss (Geschätzt)

1. Dezember 2029

Studienabschluss (Geschätzt)

1. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

3. Januar 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Januar 2023

Zuerst gepostet (Tatsächlich)

30. Januar 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • H-51929

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren